05/01/2018

Important Oncology Related News

They are called 'co-pay accumulators,' and they're a way insurers make you pay more for Meds

By David Lazarus, April 27, 2018 - Many insurers are introducing so-called copay accumulators to their plans. What this means is that coupons no longer will be counted toward patients' deductibles.  READ MORE

RITUXAN HYCELA C-CODE FOR HOSPITAL OUTPATIENT SETTING

The following is important information regarding a unique C-code that was recently assigned to RITUXAN HYCELA™ (rituximab/hyaluronidase human) by the Centers for Medicare & Medicaid Services (CMS). The C-code for RITUXAN HYCELA is C9467 (Injection, rituximab and hyaluronidase, 10 mg).

The unique C-code went into effect on April 1, 2018. Payers may require its use until a permanent J-code is assigned. The permanent J-code is expected to be available for use starting on January 1, 2019.

The C-code is used primarily in the Medicare hospital outpatient setting. Please check with your MAC to verify codes and any special billing requirements.

For more information about Genentech BioOncology Access Solutions call (888) 249‐4918 or visit Genentech-Access.com/ RITUXANHYCELA.

COA Statement On 340B Optimization Act

(COA) Apr 24, 2018 - “Years of independent studies and investigations have uncovered that the 340B program is out of control in many hospitals and is not functioning to help patients in need,” Ted Okon, executive director, COA. READ PRESS RELEASE

CMS to Recast 'Meaningful Use' Data Reporting Rules

(Medscape Medical News) Apr 25, 2018 - The Trump administration intends to use the annual update of the Medicare payment rule to rebrand and streamline electronic data reporting requirements, abandoning the much derided "meaningful use" name. READ ARTICLE (free registration required)